XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating activities    
Net loss $ (118,598) $ (146,234)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,829 1,654
Stock-based compensation expense 22,359 26,729
Inventory write-offs, net 2,894  
Non-cash accretion of discount on marketable securities (2,234)  
Non-cash interest expense from amortization of debt discount & issuance costs 1,229 4,677
Non-cash operating lease expense 1,278 1,221
Option payment to Shanghai Junshi Biosciences Ltd. ("Junshi Biosciences")   35,000
Loss on debt extinguishment   6,222
Other non-cash adjustments, net (829) (13)
Changes in operating assets and liabilities:    
Trade receivables, net (31,350) 7,327
Inventory (15,715) (14,203)
Prepaid manufacturing 302 6,490
Other prepaid, current and non-current assets 4,785 (6,223)
Accounts payable 17,786 1,423
Accrued rebates, fees and reserves 26,383 (14,480)
Accrued compensation (8,472) (5,086)
Accrued and other current and non-current liabilities (9,294) (8,586)
Net cash used in operating activities (107,647) (104,082)
Investing activities    
Purchases of property and equipment (252) (1,495)
Proceeds from disposal of property and equipment 618  
Purchases of investments in marketable securities (19,507)  
Proceeds from maturities of investments in marketable securities 64,750  
Proceeds from sale of investments in marketable securities 13,282  
Option payment to Junshi Biosciences   (35,000)
Net cash provided by (used in) investing activities 58,891 (36,495)
Financing activities    
Proceeds from 2027 Term Loans, net of debt discount & issuance costs   191,190
Proceeds from issuance of common stock upon exercise of stock options 117 552
Proceeds from purchase under the employee stock purchase plan 1,337 1,655
Taxes paid related to net share settlement of RSUs (3,086) (3,300)
Repayment of 2022 Convertible Notes and premiums   (109,000)
Repayment of 2025 Term Loan, premiums and exit fees   (81,750)
Other financing activities (625) (481)
Net cash provided by (used in) financing activities 58,129 (1,134)
Net increase (decrease) in cash, cash equivalents and restricted cash 9,373 (141,711)
Cash, cash equivalents and restricted cash at beginning of period 63,987 417,635
Cash, cash equivalents and restricted cash at end of period 73,360 $ 275,924
At The Market Offering.    
Financing activities    
Proceeds from issuance of common stock under Offering, net of issuance costs 6,761  
Public Offering    
Financing activities    
Proceeds from issuance of common stock under Offering, net of issuance costs $ 53,625